Generic Name

and Brand Name

Classifica-tion Action Dosage Indication Contraindication Side Effects Nursing Responsibility

Generic Name: PregabalinBrand names: Lyrica

anticonvulsantsBinds with high affinity to the alpha2-delta site( an auxiliary subunit of voltage-gated calcium channels) in CNS tissues.

Given orally with or without food. When discontinuing LYRICA, taper gradually over a minimum of 1 week.

The maximum recommended dose of LYRICA is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Begin dosing at 50 mg three

Treatment of neuropathic pain in adults. As adjunctive therapy of partial seizures with or without secondarily generalization in patient aged 12 and above.

Hypersensitivity to the active substance or to any of the excipients. Lactation.

Neutropenia, appetite increase, anorexia, hypoglycaemia. Euphoric mood, confusion, libido decreased, irritability. Nervous system disorder i.e. dizziness, ataxia, disturbance in attention, memory impairment, tremor, dysarthria. Eye disorders i.e. blurred vision, diplopia, visual

ASSESSMENT-obtain pt history before medication.-monitor hypersensitivity of pt to drug and other component.-monitor for decreased platelet count.-monitor for elevated creatine kinase.

NSG DIAGNOSES:-risk for traumatic injury related to seizure disorder.-risk for impaired skin integrity related to dermatologic reaction.-knowledge-deficit related to drug therapy.

times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Because LYRICA is eliminated primarily by renal excretion, adjust the dose in patients with reduced renal function.

disturbances, dry eye, eye swelling, visual acuity reduced, eye pain, asthenopia, lacrimation increased. Vertigo, hyperacusis, tachycardia, AV block 1st degree, sinus tachycardia. GIT disorders i.e. dry mouth, constipation, vomiting and flatulence. General disorders i.e. fatigue, feeling drunk, peripheral edema, gait abnormality, weight increase.

PLANNING:-give by oral administration, with or without food.-store at temperature not exceeding 25 Celsius.

IMPLEMENTATION:- Instruct patient to notify prescriber if shehas changes in vision or unexplained musclepain, tenderness, or weakness, especiallyif these muscle symptoms are accompaniedby malaise or fever.- Alert patient that drug may cause edemaand weight gain.-Inform male patient who plans to father achild that drug could impair his fertility.

- Instruct diabetic patients to inspect theirskin while taking pregabalin.

EVALUATION:-pt does not exp. Seizure.-decreased in severity of seizures.-pt does not develop drug induced adverse reactions.-pt and family state understanding of drug therapy.